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The dynamics of endothelial dysfunction (ED) humoral factors: a soluble form of vascular cell adhesion molecule 1 
(sVCAM-1), total NO metabolites and systemic inflammatory response - C-reactive protein (CRP) in patients with 
acute myocardial infarction (MI) under the influence of treatment and depending on genes polymorphism – 
angiotensin converting enzyme (ACE, I/D) and endothelial nitric oxide synthase (eNOS, T894G) were evaluated. 
The presence of DD-genotype of ACE gene is associated with a significantly greater decrease of sVCAM-1 and 
CRP levels under the influence of treatment (better with thrombolytic therapy (TLT), p<0.05); in T- allele carriers of 
eNOS gene the level sVCAM-1 under TLT decreased by 30.7-31.2%. Content of NO metabolites decreased more in 
D-allele carriers of ACE gene as well as after combined treatment with TLT (39.1% and 35.2%) and did not depend 
on the allele state of eNOS gene. 
Keyword: ACE (I/D), eNOS (894G>T) genes, myocardial infarction, endothelium, treatment 
 
1. Introduction 
The imbalance between protective and disturbing 
humoral factors (nitric monoxide (NO), activity 
of endothelial nitric oxide synthase (eNOS), 
endothelial hyperpolarizing factor, PgI, 
endothelin-1, thromboxan-A2 etc.) as well as 
anti-inflammatory cytokines, chemoattractants, 
adhesion molecules (soluble form of vascular cell 
adhesive molecule (sVCAM), L-, E-selectins, 
intensification of oxidizing stress processes, 
hemodynamic changes (under conditions of intact 
endothelium the pressure of laminar blood flow 
on the vascular wall (shear stress)) result in the 
release of endogenic NO [1-3]. On the contrary, 
blood flow turbulence in case of vasospasm or in 
the places of arterial trunk bifurcations changes 
orientation of endothelial cells and decreases NO 
release, dyslipidemia, mutations of associated 
genes etc., creating preconditions for the 
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development and progress both endothelial 
dysfunction and atherosclerosis [3-6]. Increased 
NO synthesis with accumulation of its final 
metabolites under conditions of acute endothelial 
damage with acute coronary syndrome (ACS) 
may have a cytotoxic effect, because accumulated 
superoxide radical (О2-), as a result of activation 
of free radical lipid damage processes, interacting 
with NO create a highly active oxidant – 
peroxynitrite (ONOO-) causing additional 
oxidation of the damaged tissues leads to 
endothelial dysfunction (ED), with clinical 
consequences and myocardial infarction (MI) 
among them [2, 5, 7, 8]. The genetic dependence 
concerning the development and severity of ED 
with the aim to differentiate high risk groups of 
cardiovascular diseases or ACS occurrence has 
been extensively studied over the past decade [7, 9- 
11]. But in Eastern Europe, such studies are 
extremely insufficient [6, 7, 9, 12].  
Consequently, the aim of our study was to 
analyze the dynamics of ED humoral factors 
(sVCAM-1, total NO metabolites) and systemic 
inflammatory response – C-reactive protein 
(CRP) in patients with ACS under the influence 
of treatment depending on genes polymorphism 
of angiotensin converting enzyme (ACE, I/D, rs 
4646994) and eNOS (894G>T, rs1799983).  
 
2. Materials and Methods 
2.1 Compliance with bioethics 
The study was performed in compliance with the 
Council of Europe Convention on Human Rights 
and Biomedicine and the Recommendations of 
the Committee on Bioethics of the Ministry of 
Public Health of Ukraine. Patients' Examination 
Cards and Patients' Informed Consent Forms 
were approved by the Biomedical Ethics 
Commission of Bukovinian State Medical 
University, the Ministry of Public Health of 
Ukraine (Chernivtsi, Ukraine). All enrolled 
patients were treated in the Regional Clinical 
Cardiologic Hospital (Chernivtsi, Ukraine) during 
2010-2013 y.y. Genetic bench studies performed 
in the laboratory of the Department of Medical 
Biology and Genetics of Bukovinian State 
Medical University. After screening (matching  
inclusion/exclusion criteria) 102 acute MI 
patients were selected for further examination. 
The control group included 30  practically 
healthy individuals. 
 
2.2 Inclusion / Exclusion criteria 
Inclusion criteria. The presence of typical 
anginal pain at rest lasting more than 20 minutes, 
which is not eliminated by nitroglycerin; ECG 
changes (persistent elevation of ST segment, in at 
least two contiguous leads ≥0,25 mV in men 
before 40 years, ≥0,20 mV in men over 40 years, 
≥0,15 mV in women in leads V2-V3, and/or ≥0,10 
mV in other leads (in the absence of left 
ventricular hypertrophy (LVH), or blockade of 
left bundle branch block), first onset of left 
bundle branch block and/or pathological Q-
wave), in accordance with national and ESC 
guidelines (2012) [13-15]; age above 20 y.o.; 
voluntary consent to participate in the study. 
 
Exclusion criteria. We excluded patients with 
chronic heart failure (CHF) higher than II 
functional class (NYHA III-IV), true cardiogenic 
shock, type I diabetes, sub- and decompensated 
type II diabetes, malignant uncontrolled arterial 
hypertension (AH), sub- and decompensated 
diseases of the liver (three times over the norm 
level of aspartate aminotransferase, alanine 
aminotransferase) and kidneys (blood serum 
creatinine 200 mkmol/l and higher), bronchial 
asthma, chronic obstructive pulmonary disease of 
III-IV stage (GOLD 2011), exacerbated 
oncologic and infectious diseases or during 
unstable remission, psychological disorders. 
 
2.3 Diagnosis of Myocardial Infarction 
Selection of patients and their distribution into 
groups was performed according to the 
Recommendation of Ukrainian and European 
Society of Cardiology (ESC, 2012) [13-15]. The 
clinical diagnosis of MI was made on the basis of 
clinical findings, ECG and biochemical 
examinations, the biomarkers troponin-T (cTnT) 
of myocardium damage according to the current 
national and international recommendations [13-
15]. 
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All patients were examined comprehensively: 
general clinical, ECG, laboratory and 
instrumental examination (EchoCG). 
 
2.4 Endothelium Dysfunction humoral factors 
and systemic inflammatory response 
investigation 
Total stable metabolites of nitric oxide (NO2-
+NO3-) and sVCAM-1 were detected in the blood 
plasma of patients with MI stabilized with EDTA 
(1 mg/mL): NO metabolites – by means of 
calorimetric method (Assay Kit) with the set of 
reagents of the "Total NO/NO2-/NO3-" (RDS, 
Great Britain); sVCAM-1 – by immune-enzyme 
analysis (ILISA) with the set of reagents of 
"Diaclone" (France). The content of CRP in the 
blood serum was studied by ELISA with the sets 
of reagents of "Quantikine®" (R&D Systems, 
Inc., USA). NO metabolites levels, sVCAM-1 
and CRP were detected in 88 patients before and 
after the treatment.  
 
2.5 Principles of Myocardial Infarction 
Management 
Basic pharmacotherapy of patients with MI 
included into the study during the whole period of 
examination was conducted according to the 
current legal national and international 
recommendations and protocols [13-15]. Among 
them, 50 patients received thrombolytic therapy 
(TLT) with Streptokinase /or Alteplase/ or 
Tenecteplase according to the algorithm of 
administration for this medicine. The period of 
observation was 12 months ± 2-3 weeks. 
 
2.6 Genotyping of the ACE – I/D and eNOS – 
894G>T polymorphisms  
Genomic DNA was extracted from peripheral 
blood leukocytes using the "DNA-sorb-B" test 
system, with primers specific to the genes' alleles 
[16]. Detection of I/D polymorphism of ACE gene 
and 894G>T polymorphism of eNOS gene was 
performed by the multiplex polymerase chain 
reaction (PCR) according to the manufacturer’s 
protocol. Allele-specific primers were used in the 
PCR (Table 1). The PCR products for 894G>T 
polymorphism of eNOS gene detection were 
digested overnight by restriction endonuclease 
Ban II (Eco241) for G-allele+ (Fermentas, 
Lithuania) at 37 °C. The PCR products (for ACE 
gene – II genotype 553 bp, ID – 553 and 263 bp, 
DD – 263 bp; for eNOS gene – TT genotype - 
250 bp,  GG – 160 and 90 bp, TG – 250, 160 and 
90 bp) were separated by horizontal 
electrophoresis on 3% agarose gels, stained with 
4 μl of ethidium-bromide and visualized by in the 
presence of molecular mass ladder (100-1000 bp) 
using a UV transilluminatior (Nyxtechnic, USA) 
(Figures 1, 2). 
 
Table 1: Primer sequences for ACE (I/D) and eNOS (T894G) gene SNP and size of fragments
 
SNP 
locus Primers Primer sequences (5’-3’) Size of fragments, bp 
АСЕ 
I/D 
Forward 5–GCCGGGGACTCTGTAAGCCACTGC–3’ Allele I: 553 bp 
Allele D: 263 bp Reverse 5’–CCTTGTCTCGCCAGCCCTCCCA–3’ 
eNOS 
894G>T 
Forward 5–ATGAAGGCAGGAGACAGTGGATGG–3’ Allele G: 160, 90 bp 
Allele T: 250 bp Reverse 5’–CCAGTCAATCCCTTTGGTGCTCA–3’ 
bp – base pair 
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Fig 1: Electrophoregramm of human DNA PCR products amplification of ACE I/D gene 
polymorphism. Note: L – DNA Ladder "GeneRuler 100 bp" (1000-100 bp); lines 1, 4 – homozygous 
II genotype; lines 2, 5 – heterozygous ID variant; lines 3, 6 – homozygous DD variant. 
 
 
Fig 2: Electrophoregramm of human DNA PCR products amplification of eNOS 894T>G gene 
polymorphism. Note: L – DNA Ladder "GeneRuler 100 bp" (1000-100 bp); lines 1, 4, 7, 8 – 
heterozygous TG variant; lines 2, 3, 5, 6 – homozygous TT variant. 
 
2.7 Statistical analysis: Statistical analysis was 
performed using Statistica 7.0 (StatSoft Inc, 
USA) software, by parametric and nonparametric 
methods of calculation. P value and odds ratio 
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(OR), with 95% confidence interval (CI) using a 
chi-square test were determined for the calculated 
frequencies of each allele and genotypes. Risk 
ratios (RR) were estimated by OR. Adjusted OR 
and 95%CI were estimated for an association 
between age, Q-MI, non-Q-MI and genetic 
polymorphism. Parametric data are reported as 
mean±S.D. Continuous variables were tested for 
normal distribution by the Kolmogorov-Smirnov 
test. When data were not normally distributed, 
they were logarithmically transformed before 
statistical analysis. P values <0.05 were 
considered statistically significant. 
 
3. Results and Discussions 
102 patients with acute MI were screened. 
Patients were selected and divided into groups by 
the type of myocardial infarction (MI) (Q-, not Q-
MI), localization (anterior, inferior myocardial 
wall of the left ventricle (LV)), succession of 
development (first, repeated or recurrent) 
according to the Recommendation of the National 
Ukrainian (2013) and European Society of 
Cardiology (ESC, 2012) [13-15]: 92 (90.2%) 
patients with Q-MI and stable ST segment 
elevation, and 10 (9.8%) patients with non Q-MI 
without ST segment elevation. There were 15 
women (14.7%) and 87 men (85.3%) with an 
average age 60.7±4.25 (from 22 to 83 y.o.). The 
reference group included 30 practically healthy 
individuals with corresponding sex distribution 
without relative relations with the study group 
patients.  
The levels of sVCAM-1, NO metabolites and 
CRP in the blood of patients with Q-MI before 
treatment (Table 2) were 28.9%, 18.6% and 
47.1% higher than in the non Q-MI patients 
respectively (р<0.05). A considerable dynamics 
of indices depending on the succession of MI 
occurrence was not found. Although, inferior 
localization of MI was accompanied by a 33.8% 
increase of sVCAM-1 content as compared with 
the anterior localization (р=0.028).  
 
Table 2: Humoral Markers of Endothelial Dysfunction and Inflammation Depending on the Type of 
Myocardial Infarction, Sequence of Its Occurrence and Localization, M±S.D. 
Observed Groups sVCAM-1, ng/mL 
NO/NO2-/NO3-, 
mkmol/L CRP, mg/L 
Control 953.0±147.3 21,05±2.71 2.15±0.84 
Type of MI 
Q-MI, n=78 1512.0±176.1 
р<0.01 46.7±2.09 р<0.001 13.1±2.56 р<0.001 
non Q-MI, 
n=10 
1075.0±201,9 
р1=0.046 
38.0±3.97 
р<0.001 р1<0.05 
6.93±2.12 
р<0.05 р1=0.035 
Sequence of 
MI 
Primary MI, 
n=63 1395.0±197.9 45.9±5.88 р<0.001 10.5±2.26 р<0.001 
Repeated 
MI, n=25 
1364.0±85.1 
р<0.05 
42.5±3.17 
р<0.001 7.65±2.12 р<0.01 
Localization 
of MI 
Anterior, 
n=46 1325.0±141.3 42.9±3.15 р<0.001 12.6±2.64 р<0.001 
Inferior, 
n=42 
2002.0±391.4 
р<0.01 р1=0.028 
47.2±4.94 р<0.001 9.90±3.61 р<0.001 
Notes: MI – myocardial infarction; NO/NO2-/NO3- – total NO/nitrite/nitrate; sVCAM-1 (CD 106) – 
soluble vascular cell adhesive molecule; СRP – С-reactive protein. р – reliability of differences 
considering the control group; р1 – reliability of differences between Q-, non Q-MI; р2 – reliability of 
differences of indices between patients with primary MI and a repeated / or recurrent MI; р3 – 
reliability of differences between anterior and inferior MI. 
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Under the influence of treatment a reliable 
dynamics of humoral markers of ED and 
inflammation was observed (Table 3): decrease of 
sVCAM-1 plasma levels, total NO and serum 
CRP in 27-28 days and six months by 1.4-2.3 
times (р<0.01-0.001) and 1.5-2.0 times (р<0.01-
0.001) respectively. It should be noted that 
administered thrombolytic therapy (TLT) 
promoted a reliable additional 17.2% decrease of 
toxic levels of NO metabolites as compared with 
the treatment without TLT (р<0.05). 
 
Table 3: Humoral Markers of Endothelial Dysfunction and Inflammation in Patients with Myocardial 
Infarction after 28 Days and 6 Months of Treatment and observation, M±S.D. 
Parameters Before treatment, n=88 
27-28 days of treatment, n =44 6 months of 
observation, n=44 After TLT, n=24 
Without TLT, 
n=20 
sVCAM-1, ng/mL 1258.6±97.0 801.0±61.3 
р<0.001 
844.9±83.2 
р<0.001 850.3±102.4 р<0.01 
NO/NO2-/NO3-, 
mkmol/L 45.7±4.01 
28.8±2.02 
р<0.001 
34.8±2.76 р<0.01 
р1<0.05 
27.5±4.22 р<0.001 
р2<0.05 
CRP, mg/L 10.3±1.02 4.15±0.97 
р<0.001 
4.74±1.01 
р<0.001 
5.08±1.42 
р<0.001 
Notes: TLT – thrombolytic therapy; NO/NO2-/NO3- – total NO/nitrite/nitrate; sVCAM-1 (CD 106) – 
soluble form of vascular cell adhesive molecule; СRP – С-reactive protein. р – reliability of data 
differences concerning the condition before treatment; р1 – reliability of differences with the results of 
patients 27-28 days after TLT treatment; р2 – reliability of differences with the results of patients 27-28 
days after treatment without TLT.
 
 
 
Table 4: Plasma Content of a Soluble Form of Vascular Cell Adhesive Molecule-1 (ng/mL) in Patients 
with Myocardial Infarction on the 28th Day of Treatment and 6 months of Observation Depending on 
АСЕ (I/D) and eNOS (894G>T) Genes Polymorphisms, M±S.D. 
Genotypes of the 
analyzed genes 
Before 
treatment, n=88 
27-28 days of treatment, n=44 6 months of 
observation, n=44 After TLT, 
n=24 
Without TLT, 
n=20 
АСЕ 
II 903.6±195.5 742.5±98.7 764.4±89.4 766.9±109.5 
I/D 875.4±143.9 779.2±80.1 800.1±113.6 803.9±125.3 
DD 1457±137.7 II,I/D 
1029±99.0 
р<0.05 II. I/D 
1050±110.5 
р<0.05 II. I/D 
1103±92.8 
р<0.05 II, I/D 
eNOS 
GG 1273±154.5 901.0±67.1 
р<0.05 938.9±118.5 941.7±128.4 
TG, ТТ 1183±110.3 792.2±85.8 
р<0.05 
813.9±80.3 
р<0.05 819.6±104.3 р<0.05 
Notes: TLT – thrombolytic therapy. р – reliability of differences concerning the condition before 
treatment separately for every genotype; р1 – reliability of differences after TLT separately for every 
genotype; р2 – reliability of differences without TLT separately for every genotype. 3. Squared 
genotype – reliability of indices differences (р<0.05) concerning the genotype indicated within every 
gene (vertically) separately 28 days after treatment and 6 months of observation.
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Depending on the analyzed genes' genotypes 
distribution (Table 4) statistically important 
decrease of sVCAM-1 after treatment both on the 
28th day at the hospital and 6 months of the 
observation was found in the DD-genotype 
carriers of ACE gene, better with  basic TLT – by 
29.4% and 27.9% (р<0.05 ) and 24.3% (р<0.05) 
respectively. Herewith, sVCAM-1 in DD-
genotype carriers was still higher than in the 
"wild" I-allele carriers (р<0.05). Depending on 
the genotypes of eNOS gene, TLT promoted a 
reliable decrease of sVCAM-1 in both groups by 
29.2% and 33.0% respectively (р<0.05). 
Although, without TLT after 6 months treatment 
and observation considerable changes were found 
only in the "mutant" T-allele carriers by 31.2%  
and 30.7% respectively (р<0.05). Reliable 
differences between the genotypes of eNOS gene 
were not found 
CRP reliably decreased after treatment in all the 
groups observed with statistically important 
benefit in DD-genotype carriers of ACE gene: 
with TLT – by 2.84 times (p<0.001), without 
TLT – by 2.15 times (p<0.001). In addition, the 
use of TLT promoted a more considerable 
decrease of CRP – on 24.3% (р<0.05) (Table 5). 
Despite a strong effect of the treatment the level 
of CRP in the DD-genotype carriers was higher 
than in I-allele carriers (р<0.05). Reliable 
differences of CRP content during treatment 
between the eNOS gene genotypes were not 
found. 
 
 
 
Table 5: Serum Content of C-reactive Protein (mg/L) in Patients with Myocardial Infarction on the 28th 
Day of Treatment and after 6 Months of Observation Depending on АСЕ (I/D) and eNOS (894G>T) 
Genes Polymorphisms, M±S.D. 
Genotypes of 
genes analyzed 
Before 
treatment, 
n=88 
27-28 days of treatment, n=44 6 months of 
observation, n=44 After TLT, 
n=24 
Without TLT, 
n=20 
АСЕ 
II 11.7±4.08 4.18±0.52 
р<0.001 5.03±0.69 р<0.01 5.38±1.44 р<0.05 
I/D 11.6±1.68 3.98±0.71 
р<0.001 4.67±0.93 р<0.001 4.97±1.05 р<0.001 
DD 19.6±2.86 II, I/D 
6.90±1.04 
II, I/D р<0.001 
9.12±1.10 
II, I/D р<0.001 
р1=0.049 
8.80±1.27 
II, I/D р<0.001 
eNOS 
GG 12.7±1.90 4.95±1.09 
р<0.001 5.43±0.97 р<0.001 5.51±0.82 р<0.001 
TG, ТТ 12.1±1.55 4.18±0.65 
р<0.001 4.69±1.12 р<0.001 5.04±1.07 р<0.001 
    Note: similarly to Table 4.
 
The plasma content of total stable NO 
metabolites was reliably decreased after treatment 
(Table 6): in the D-allele carriers of ACE gene 
with TLT – by 39.1% and 35.2% (р<0.001) and 
without TLT – by 26.6% and 25.4% (р<0.001), 
with a reliable difference between them – by 
17.0% and 13.2%, respectively (р<0.05). In 
addition, during the whole period of treatment 
NO level in the DD-genotype carriers were 
higher than in the II-genotype carriers by 16.6- 
27.1% (р<0.05). eNOS gene genotypes 
distribution did not influence reliably on the NO 
metabolites concentration during the course of 
treatment (Table 6). Although, TLT promoted 
13.0% decrease of NO in the GG-genotype 
carriers (р<0.05) and 11.1% decrease in the T-
allele carriers of eNOS gene (р<0.05). 
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Table 6: Total NO Metabolites Plasma Content (mkmol/L) in Patients with Myocardial Infarction on 
the 28th Day of Treatment and 6 Months of Observation Depending on АСЕ (I/D) and eNOS (894G>T) 
Genes Polymorphisms, M±S.D. 
Genotypes of 
genes analyzed 
Before 
treatment, 
n=88 
27-28 days of treatment, n=44 6 months of 
observation, n=44 After TLT, 
n=24 
Without TLT, 
n=20 
АСЕ 
II 43.0±3.22 26.5±2.17 
р<0.001 28.0±3.90 р<0.001 25.6±2.15 р<0.001 
I/D 45.8±5.15 27.9±1.88 
р<0.001 
33.6±2.75 р<0.001 
р1<0.05 
27.8±2.29 р<0.001 
р2<0.05 
DD 47.7±2.64 30.9±1.38 
II 
р<0.001 
35.6±1.20 II 
р<0.001 р1<0.05 
32.0±2.07 II р<0.001 
р2=0.051 
eNOS 
GG 40.1±2.10 26.8±2.41 
р<0.001 
30.8±1.13 р<0.001 
р1<0.05 
27.1±2.46 р<0.001 
р2=0.053 
TG, ТТ 46.6±4.78 28.1±2.20 
р<0.001 
31.6±1.06 р<0.001 
р1<0.05 
27.9±3.19 р<0.001 
   Note: similarly to Table 4.
 
 
Epidemiological analysis showed that sVCAM-1 
is a potential risk factor of Q-MI (OR=4.51, 
95%CI OR=1.57-13.0, р=0.003), irrespective of 
MI localization and sequence of occurrence 
(more pronounced in case of inferior localization 
and repeated occurrence OR=5.40, 95% СІ 
OR=1.77-17.1, р=0.002 and OR=7.50, 95%CI 
OR=2.15-26.2, р=0.001, respectively). Increased 
content of NO metabolites (≥45 mkmol/L) is a 
risk marker of MI regardless of its type, 
localization and sequence. CRP increases the risk 
of Q-MI occurrence by 2.16 times (OR=3.75, 
95%CI OR=1.49-9.46, р=0,004), on the anterior 
myocardial wall of the left ventricle – by 2.77 
times (OR=7.79, 95% СI OR=2.75-22.1, 
р<0.0001), for the first time MI onset – by 2.08 
times (OR=3.44, 95% CI OR=1.33-8.88, 
р=0.009). 
In general, our results coincide with the findings 
of other researchers. Some of them proved that 
moderate NO hyperproduction improves tissue 
perfusion by means of vasodilatation, inhibits 
adhesion and aggregation of platelets, reveals 
anti-thrombotic action, and the reduction of 
leukocyte-endothelial adhesion can prevent 
occurrence of a critical stage of an inflammatory  
reaction [1, 4, 5, 8]. Other researchers describe 
absolutely opposite effects of an increased NO 
level [3, 11], considering that NO hyperproduction 
results in cytotoxic effects, apoptosis initiation, 
dilation of the peri-infarction area, aggravating 
further course and prognosis of MI. There is 
convincing evidence proving that endothelial 
dysfunction is interrelated with the systemic 
inflammation factors – CRP, pro-inflammatory 
cytokines, lipid and carbohydrate metabolism 
disorders, oxidant stress etc. in patients with MI 
[11, 17]. The combination of the above mentioned 
factors increases the risk of MI development [11, 
17]. 
 
4. Conclusion 
Q-MI is accompanied with 18.6-47.1% growth of 
humoral markers of endothelial damage 
(sVCAM-1, total stable NO metabolites) and 
inflammation (CRP), that intensified with inferior 
localization of MI. DD-genotype of АСЕ gene 
and ТТ-genotype of eNOS gene are associated 
with higher levels of sVCAM-1 and CRP by 
19.1-40.8%, as well as NO metabolites in the ТТ-
genotype carriers by 23.7%, which is indicative 
of more severe endothelial dysfunction due to  
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excessive synthesis of nitrite-anion and absence 
of an adequate coronary vessels compensatory 
response. 
Increasing of sVCAM is a potential risk factor of 
Q-MI (OR=4.51), regardless of its localization 
and sequence of occurrence. Increase of NO 
metabolites increases the risk of MI by 4.43-4.80 
times, irrespective of its type, localization and 
sequence. CRP increases the risk of Q-MI 
occurrence in 2.16 times (OR=3.75), on the 
anterior myocardial wall of the left ventricle – in 
2.77 times (OR=7.79), primary occurrence – in 
2.08 times (OR=3.44). 
Complex therapy of MI promoted a reliable 
decrease of humoral markers of endothelial 
dysfunction and inflammation 27-28 days after 
treatment in 1.4-2.3 times, 6 months after 
observation – in 1.5-2.0 times. TLT 
administration promoted an additional reliable 
decrease of toxic levels of NO metabolites by 
17.2%. DD-genotype of АСЕ gene is associated 
with a reliably greater decrease of sVCAM-1 and 
CRP levels after treatment, both 28 days in the 
hospital and 6 months of observation (better after 
TLT); in T-allele carriers of eNOS gene the level 
of sVCAM-1 after TLT was 30.7-31.2% lower. 
The NO metabolite content became less after the 
treatment with the use of TLT in the D-allele 
carriers of АСЕ gene (by 39.1% and 35.2%) and 
it did not depend on the allele content of eNOS 
gene.  
 
Prospects of Research: molecular-genetic 
investigations of MI patients; prognosis of acute 
MI depending on genetic factors.  
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